New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:53 EDTCBMGCellular Biomedicine releases positive ReJoin Phase I/IIa six-month data
Cellular Biomedicine released the six-month follow-up data analysis of its Phase I/IIa clinical trial for its Rejoin human adipose-derived mesenchymal precursor cell, or haMPC, therapy for Knee Osteoarthritis, or KOA. The trial, conducted by Shanghai Renji Hospital, tested the safety and efficacy of intra-articular injections of autologous haMPCs in order to reduce inflammation and repair damaged joint cartilage. The primary endpoints for this trial were safety and knee-related pain, stiffness and function measured using the Western Ontario and McMaster Universities osteoarthritis index questionnaire. The secondary endpoints were cartilage repair at six months, defined through the volume of the repair tissue measured with quantitative magnetic resonance imaging as well as NRS-11, SF-36 and KSCRS scores.
News For CBMG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 16, 2014
08:35 EDTCBMGCellular Biomedicine launches pre-clinical research study for COPD
Cellular Biomedicine announced the launch of a pre-clinical study of human adipose-derived mesenchymal progenitor cell, or haMPC, therapy for Chronic Obstructive Pulmonary Disease, or COPD. The study will evaluate the safety and efficacy of haMPCs to treat COPD. The pre-clinical study will be conducted by Shanghai First People's Hospital, a leading teaching hospital affiliated with Shanghai Jiaotong University. Professor Zhou Xin, director of the hospital's respiratory department and chairperson of Respiratory Diseases Division of Shanghai Medical Association, will lead the study as Principal Investigator. Prof. Zhou is also currently leading the Company's pre-clinical study on adipose derived mesenchymal progenitor cell therapy for asthma.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use